Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice

1 May 2018

Abstract excerpt

The circadian glucocorticoid-Krppel-like factor 15-branched-chain amino acid (GC-KLF15-BCAA) signaling pathway is a key regulatory axis in muscle, whose imbalance has wide-reaching effects on metabolic homeostasis. Spinal muscular atrophy (SMA) is a neuromuscular disorder also characterized by intrinsic muscle pathologies, metabolic abnormalities and disrupted sleep patterns, which can influence or be influenced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Congenital Anomalies and Fetal Surgery
Share to Neurogenetic and Muscular Disorders Research
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29735415
DOI: 10.1016/j.ebiom.2018.04.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy MicePMID 29735415Read ↗

Mifepristone alone and in combination with scAAV9- <i>SMN1</i> gene therapy improves disease phenotypes in <i> Smn <sup>2B/-</sup> </i> spinal muscular atrophy miceSemantic proximity Read ↗

A transcriptomics-based drug repositioning approach to identify drugs with similar activities for the treatment of muscle pathologies in spinal muscular atrophy (SMA) modelsSemantic proximity Read ↗

A transcriptomics-based drug repositioning approach to identify drugs with similar activities for the treatment of muscle pathologies in spinal muscular atrophy (SMA) modelsSemantic proximity Read ↗

Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy miceSemantic proximity Read ↗

Systemic Factors Affect Bone Health in SMA Type II Patients and a Mouse Model of SMASemantic proximity Read ↗

Genetic Variability in Oxidative Stress, Inflammatory, and Neurodevelopmental Pathways: Impact on the Susceptibility and Course of Spinal Muscular Atrophy.Semantic proximity Read ↗

A severe mouse model of spinal muscular atrophy develops early systemic inflammationSemantic proximity Read ↗

Dysregulation of the Tweak/Fn14 pathway in skeletal muscle of spinal muscular atrophy miceSemantic proximity Read ↗

Fibroblast growth factor-21 induces skeletal muscle atrophy and increases plasma amino acids in female mice: a potential role for glucocorticoidsSemantic proximity Read ↗

Metabolic Dysfunction in Spinal Muscular Atrophy.Semantic proximity Read ↗

Metformin extends the lifespan of iMSUD mice by rescuing physiologic dysfunction and modulating mechanisms of mTORC1 activationSemantic proximity Read ↗

Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.